Piper Sandler raised the firm’s price target on Humana (HUM) to $288 from $270 and keeps a Neutral rating on the shares. The firm says its 2026 adjusted EPS reflects what it believes is the floor for QBP and does not represent the earnings power of the organization. Piper thinks Star Ratings recovery will be a multi-year process at Humana.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM: